USFDAMay 19, 2026, 07:02 AM
Cullinan CLN-049 Receives FDA Orphan Drug Designation for AML
AI Summary
Cullinan Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLN-049, its novel FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute myeloid leukemia (AML). This designation underscores the urgent need for new therapies in AML, particularly for patients with TP53-mutated AML who face a poor prognosis. The Orphan Drug Designation provides significant development incentives, including tax credits, exemption from certain FDA user fees, and potential seven years of market exclusivity post-approval. CLN-049 is also currently undergoing Phase 1 studies and has previously received Fast Track designation for R/R AML.
Key Highlights
- Cullinan Therapeutics' CLN-049 received FDA Orphan Drug Designation for relapsed/refractory acute myeloid leukemia (AML).
- The designation provides incentives including tax credits, user fee exemption, and potential 7 years of market exclusivity.
- CLN-049 is a novel, investigational FLT3xCD3 T cell engager designed for AML and myelodysplastic syndrome (MDS).
- It targets both mutated and non-mutated FLT3, making it applicable to a broad patient population.
- CLN-049 is currently being studied in two parallel Phase 1 clinical trials for AML/MDS.
- The drug previously received Fast Track designation from the FDA for relapsed/refractory AML.
- AML affects approximately 22,000 people annually in the U.S. and 144,000 globally.
- Five-year survival for patients with relapsed or refractory AML is 10% or less.
Price Impact
More from CGEM